Nurs Womens Health. 2020 Jun;24(3):233-237. doi: 10.1016/j.nwh.2020.03.003. Epub 2020 May 6.
Sickle cell disease is an inherited disorder that affects more than 100,000 individuals in the United States and results in a shortened life span. Characterized by the production of abnormal, sickle-shaped hemoglobin, the disease is marked by anemia, vaso-occlusion of blood vessels, and tissue damage. In November 2019, the U.S. Food and Drug Administration approved voxelotor (Oxbryta) as a novel treatment for sickle cell disease. Voxelotor inhibits the production of sickle hemoglobin and improves anemia. This article presents an overview of voxelotor, including adverse effects, use in special populations, and implications for nursing practice.
镰状细胞病是一种遗传性疾病，影响美国超过 100,000 人，导致寿命缩短。该病的特征是产生异常的镰状血红蛋白，表现为贫血、血管阻塞和组织损伤。2019 年 11 月，美国食品和药物管理局批准了 voxeloTOR（Oxbryta）作为镰状细胞病的一种新疗法。VoxeloTOR 抑制镰状血红蛋白的产生并改善贫血。本文介绍了 voxeloTOR，包括不良反应、特殊人群的应用及对护理实践的影响。
